The Latest Cardiac and Vascular News
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for its Freesolve™ Resorbable Magnesium Scaffold (RMS) for percutaneous coronary intervention (PCI). To qualify for a BDD, device technology must address an unmet clinical need and show that it has the potential to provide for more effective treatment of life-threateni
BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effective ALAMEDA, Calif., Oct. 20, 2026 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced that the U.S. Food and Drug Administration (FDA) […]
IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical […]
Real-world data from 47 U.S. health systems shows three-year survival of 76% among systolic heart failure patients prescribed four GDMT classes, versus 52% among those prescribed none ALISO VIEJO, Calif., Oct. 21, 2026 /PRNewswire/ — egnite, Inc., a technology company advancing…
MIAMI, Oct. 21, 2026 /PRNewswire/ — Resolve Therapeutics, LLC, a clinical-stage biotechnology company developing nuclease-Fc fusion proteins designed to degrade pathogenic extracellular nucleic acids, today announced two e-posters featuring preclinical data on its RNase-Fc fusion protein…
VANCOUVER, British Columbia–(BUSINESS WIRE)–Kardium today announced the first site activation and first patient enrollment in the Globe Registry: Globe® Pulsed Field System Registry for Treating Patients with Symptomatic Atrial Fibrillation. The registry marks an important milestone in the continued commercial adoption of the Globe System following positive physician experience, strong procedural outcomes, and a growing body of evidence supporting the system’s unique integrated mapping and ab
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced two milestones for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the NanoKnife System. The first is the publication of results from the DIRECT study in The Oncologist, in
BOSTON–(BUSINESS WIRE)– #510k–Elucid has received FDA 510(k) clearance of FFR-IQ™, its software for noninvasive estimation of fractional flow reserve from coronary CT angiography.
SAN DIEGO–(BUSINESS WIRE)– #Medtech–Vektor Medical, a medical technology company advancing the treatment of cardiac arrhythmias through its non-invasive, AI-based arrhythmia analysis technology, vMap®, today announced the completion of patient enrollment in its IMPRoVED-AF randomized clinical study and the appointment of Brandon Allen as Senior Vice President of Sales. Together, these milestones mark important progress in Vektor’s efforts to expand commercial adoption of vMap and strengthen the clinica
SUNNYVALE, Calif.–(BUSINESS WIRE)–EBR Systems, Inc., developer of the world’s only left ventricular endocardial pacing (LVEP) system for heart failure, announces the appointment of Robert C. Canby, MD, as Chief Medical Officer. Key Highlights Robert Canby, MD, appointed Chief Medical Officer is a board-certified cardiac electrophysiologist who brings extensive experience across clinical practice, physician education, cardiovascular research, and medical device innovation. Dr. Canby practices
